Journal article
A comparison between 12 versus 20 weeks of trimethoprim-sulfamethoxazole as oral eradication treatment for melioidosis: an open-label, pragmatic, multicenter, non-inferiority, randomized controlled trial
- Abstract:
-
Background Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Oral TMP-SMX is recommended for 12 weeks in Australia and 20 weeks in Thailand.
Methods For this open-label, pragmatic, multicenter, noninferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 week...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Supplementary materials, 41.4KB, Terms of use)
-
(Preview, Version of record, 685.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/cid/ciaa1084
Authors
Funding
+ Wellcome Trust
More from this funder
Grant:
106698/Z/14/A milestone
106698/B/14/Z milestone
089275/F/09/Z milestone
089275/H/09/Z Milestone Baht
Bibliographic Details
- Publisher:
- Oxford University Press
- Journal:
- Clinical Infectious Diseases More from this journal
- Volume:
- 73
- Issue:
- 11
- Pages:
- e3627–e3633
- Publication date:
- 2020-07-29
- Acceptance date:
- 2020-07-27
- DOI:
- EISSN:
-
1537-6591
- ISSN:
-
1058-4838
- Pmid:
-
32725199
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1124969
- Local pid:
-
pubs:1124969
- Deposit date:
-
2020-11-04
Terms of use
- Copyright holder:
- Anunnatsiri et al.
- Copyright date:
- 2020
- Rights statement:
- © 2020 The Authors. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record